Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
natural killer cells
Biotech
Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Novartis previously shared an early data cut showing that none of the patients treated with the protein achieved an objective response.
Darren Incorvaia
Feb 19, 2026 2:45pm
ImmunityBio touts 15-month complete response in CAR-NK trial
Jan 16, 2026 9:19am
AbbVie halts development of Dragonfly cancer asset in midflight
Oct 29, 2025 1:47pm
ARPA-H goes all in on in vivo cell therapy
Oct 8, 2025 4:04pm
Gilead's Kite erodes $2.3B Shoreline cell therapy deal
Sep 3, 2025 3:18pm
CEO invests own cash to move NKGen toward Alzheimer’s readout
May 8, 2025 10:22am
